Cargando…

508. Biomarker elevation during COVID-19: Differences between ambulatory and hospitalized individuals

BACKGROUND: While the majority of illness due to COVID-19 does not require hospitalization, little has been described about the host inflammatory response in the ambulatory setting. Differences in the levels of inflammatory signaling proteins between outpatient and hospitalized populations could ide...

Descripción completa

Detalles Bibliográficos
Autores principales: Blair, Paul W, Lanteri, Charlotte, Striegel, Deborah, Agan, Brian, Maves, Ryan C, Chenoweth, Josh, Larson, Derek, Mende, Katrin, Colombo, Rhonda, Lindholm, David, Ganesan, Anuradha, Richard, Stephanie, Colombo, Chris, Madar, Cristian, Huprikar, Nikhil, Tribble, David, Dumler, John S, Burgess, Timothy, Clark, Danielle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7778285/
http://dx.doi.org/10.1093/ofid/ofaa439.702
_version_ 1783631099822342144
author Blair, Paul W
Lanteri, Charlotte
Striegel, Deborah
Agan, Brian
Maves, Ryan C
Chenoweth, Josh
Larson, Derek
Mende, Katrin
Colombo, Rhonda
Lindholm, David
Ganesan, Anuradha
Richard, Stephanie
Colombo, Chris
Madar, Cristian
Huprikar, Nikhil
Tribble, David
Dumler, John S
Burgess, Timothy
Burgess, Timothy
Clark, Danielle
author_facet Blair, Paul W
Lanteri, Charlotte
Striegel, Deborah
Agan, Brian
Maves, Ryan C
Chenoweth, Josh
Larson, Derek
Mende, Katrin
Colombo, Rhonda
Lindholm, David
Ganesan, Anuradha
Richard, Stephanie
Colombo, Chris
Madar, Cristian
Huprikar, Nikhil
Tribble, David
Dumler, John S
Burgess, Timothy
Burgess, Timothy
Clark, Danielle
author_sort Blair, Paul W
collection PubMed
description BACKGROUND: While the majority of illness due to COVID-19 does not require hospitalization, little has been described about the host inflammatory response in the ambulatory setting. Differences in the levels of inflammatory signaling proteins between outpatient and hospitalized populations could identify key maladaptive immune responses during COVID-19. METHODS: Samples were collected from 76 participants (41% female, mean 46.8 years of age) enrolled at five military treatment facilities between March 20, 2020 and June 17, 2020 in an ongoing prospective COVID-19 cohort. This analysis was restricted to those with positive SARS-CoV-2 (severe acute respiratory syndrome–coronavirus 2) RT-PCR testing and included hospitalized (N=29; 10 requiring an ICU stay) and non-hospitalized (N=43) participants. Severity markers (IL6, D-dimer, procalcitonin, ferritin, ICAM-1, IL5, lipocalin, RAGE, TNFR, VEGFA, IFNγ, IL1β) were measured in plasma (mg/dL) using the Ella immunoassay and natural log transformed. Univariate negative binomial regression was performed to determine relative risk of hospitalization. Using the full marker panel, we performed a Principal Component Analysis (PCA) to determine directions of maximal variance in the data. Pearson’s correlation coefficient was determined between analytes and each axis. RESULTS: Participants requiring ambulatory-, hospital-, and ICU-level care had samples collected at 44.0 (IQR: 35.0–51.0), 40.0 (13.0–51.0), and 47.5 (21.0–54.0) days, respectively. Higher unadjusted levels of IL6, D-dimer, procalcitonin, or ferritin were each associated with hospitalization (Table 1). The PCA showed a separation along axes between level of care and duration of symptoms (Fig 1). While significant correlations were noted with a number of biomarkers, PC1 most correlated with TNFR1 (r=0.88) and PC2 most correlated with IL6Ra (r=0.95). PC1 axis variation accounted for 36.5% of variance and the PC2 axis accounted for 20.0% of variance. Figure 1. Principal Component Analysis (PCA) of biomarkers by level of care and symptom duration. [Image: see text] [Image: see text] CONCLUSION: TNFR1 and IL6Ra levels correlated with differences in the proinflammatory states between hospitalized and non-hospitalized individuals including time points late in the course of illness. Further analysis of these preliminary findings is needed to evaluate for differences by stages of illness. DISCLOSURES: All Authors: No reported disclosures
format Online
Article
Text
id pubmed-7778285
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-77782852021-01-07 508. Biomarker elevation during COVID-19: Differences between ambulatory and hospitalized individuals Blair, Paul W Lanteri, Charlotte Striegel, Deborah Agan, Brian Maves, Ryan C Chenoweth, Josh Larson, Derek Mende, Katrin Colombo, Rhonda Lindholm, David Ganesan, Anuradha Richard, Stephanie Colombo, Chris Madar, Cristian Huprikar, Nikhil Tribble, David Dumler, John S Burgess, Timothy Burgess, Timothy Clark, Danielle Open Forum Infect Dis Poster Abstracts BACKGROUND: While the majority of illness due to COVID-19 does not require hospitalization, little has been described about the host inflammatory response in the ambulatory setting. Differences in the levels of inflammatory signaling proteins between outpatient and hospitalized populations could identify key maladaptive immune responses during COVID-19. METHODS: Samples were collected from 76 participants (41% female, mean 46.8 years of age) enrolled at five military treatment facilities between March 20, 2020 and June 17, 2020 in an ongoing prospective COVID-19 cohort. This analysis was restricted to those with positive SARS-CoV-2 (severe acute respiratory syndrome–coronavirus 2) RT-PCR testing and included hospitalized (N=29; 10 requiring an ICU stay) and non-hospitalized (N=43) participants. Severity markers (IL6, D-dimer, procalcitonin, ferritin, ICAM-1, IL5, lipocalin, RAGE, TNFR, VEGFA, IFNγ, IL1β) were measured in plasma (mg/dL) using the Ella immunoassay and natural log transformed. Univariate negative binomial regression was performed to determine relative risk of hospitalization. Using the full marker panel, we performed a Principal Component Analysis (PCA) to determine directions of maximal variance in the data. Pearson’s correlation coefficient was determined between analytes and each axis. RESULTS: Participants requiring ambulatory-, hospital-, and ICU-level care had samples collected at 44.0 (IQR: 35.0–51.0), 40.0 (13.0–51.0), and 47.5 (21.0–54.0) days, respectively. Higher unadjusted levels of IL6, D-dimer, procalcitonin, or ferritin were each associated with hospitalization (Table 1). The PCA showed a separation along axes between level of care and duration of symptoms (Fig 1). While significant correlations were noted with a number of biomarkers, PC1 most correlated with TNFR1 (r=0.88) and PC2 most correlated with IL6Ra (r=0.95). PC1 axis variation accounted for 36.5% of variance and the PC2 axis accounted for 20.0% of variance. Figure 1. Principal Component Analysis (PCA) of biomarkers by level of care and symptom duration. [Image: see text] [Image: see text] CONCLUSION: TNFR1 and IL6Ra levels correlated with differences in the proinflammatory states between hospitalized and non-hospitalized individuals including time points late in the course of illness. Further analysis of these preliminary findings is needed to evaluate for differences by stages of illness. DISCLOSURES: All Authors: No reported disclosures Oxford University Press 2020-12-31 /pmc/articles/PMC7778285/ http://dx.doi.org/10.1093/ofid/ofaa439.702 Text en © The Author 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Poster Abstracts
Blair, Paul W
Lanteri, Charlotte
Striegel, Deborah
Agan, Brian
Maves, Ryan C
Chenoweth, Josh
Larson, Derek
Mende, Katrin
Colombo, Rhonda
Lindholm, David
Ganesan, Anuradha
Richard, Stephanie
Colombo, Chris
Madar, Cristian
Huprikar, Nikhil
Tribble, David
Dumler, John S
Burgess, Timothy
Burgess, Timothy
Clark, Danielle
508. Biomarker elevation during COVID-19: Differences between ambulatory and hospitalized individuals
title 508. Biomarker elevation during COVID-19: Differences between ambulatory and hospitalized individuals
title_full 508. Biomarker elevation during COVID-19: Differences between ambulatory and hospitalized individuals
title_fullStr 508. Biomarker elevation during COVID-19: Differences between ambulatory and hospitalized individuals
title_full_unstemmed 508. Biomarker elevation during COVID-19: Differences between ambulatory and hospitalized individuals
title_short 508. Biomarker elevation during COVID-19: Differences between ambulatory and hospitalized individuals
title_sort 508. biomarker elevation during covid-19: differences between ambulatory and hospitalized individuals
topic Poster Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7778285/
http://dx.doi.org/10.1093/ofid/ofaa439.702
work_keys_str_mv AT blairpaulw 508biomarkerelevationduringcovid19differencesbetweenambulatoryandhospitalizedindividuals
AT lantericharlotte 508biomarkerelevationduringcovid19differencesbetweenambulatoryandhospitalizedindividuals
AT striegeldeborah 508biomarkerelevationduringcovid19differencesbetweenambulatoryandhospitalizedindividuals
AT aganbrian 508biomarkerelevationduringcovid19differencesbetweenambulatoryandhospitalizedindividuals
AT mavesryanc 508biomarkerelevationduringcovid19differencesbetweenambulatoryandhospitalizedindividuals
AT chenowethjosh 508biomarkerelevationduringcovid19differencesbetweenambulatoryandhospitalizedindividuals
AT larsonderek 508biomarkerelevationduringcovid19differencesbetweenambulatoryandhospitalizedindividuals
AT mendekatrin 508biomarkerelevationduringcovid19differencesbetweenambulatoryandhospitalizedindividuals
AT colomborhonda 508biomarkerelevationduringcovid19differencesbetweenambulatoryandhospitalizedindividuals
AT lindholmdavid 508biomarkerelevationduringcovid19differencesbetweenambulatoryandhospitalizedindividuals
AT ganesananuradha 508biomarkerelevationduringcovid19differencesbetweenambulatoryandhospitalizedindividuals
AT richardstephanie 508biomarkerelevationduringcovid19differencesbetweenambulatoryandhospitalizedindividuals
AT colombochris 508biomarkerelevationduringcovid19differencesbetweenambulatoryandhospitalizedindividuals
AT madarcristian 508biomarkerelevationduringcovid19differencesbetweenambulatoryandhospitalizedindividuals
AT huprikarnikhil 508biomarkerelevationduringcovid19differencesbetweenambulatoryandhospitalizedindividuals
AT tribbledavid 508biomarkerelevationduringcovid19differencesbetweenambulatoryandhospitalizedindividuals
AT dumlerjohns 508biomarkerelevationduringcovid19differencesbetweenambulatoryandhospitalizedindividuals
AT burgesstimothy 508biomarkerelevationduringcovid19differencesbetweenambulatoryandhospitalizedindividuals
AT burgesstimothy 508biomarkerelevationduringcovid19differencesbetweenambulatoryandhospitalizedindividuals
AT clarkdanielle 508biomarkerelevationduringcovid19differencesbetweenambulatoryandhospitalizedindividuals